Loading clinical trials...
Loading clinical trials...
A Virtual Phase 2 Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of the Combination of Famotidine and Celecoxib as a Post-exposure Prophylaxis (PEP) for Newly-infected COVID-19 Patients
Conditions
Interventions
Famotidine
Celecoxib
+1 more
Locations
15
United States
Integrated Therapeutic Solutions USA, Inc.
Newport Beach, California, United States
Integrated Therapeutic Solutions USA, Inc.
Miami, Florida, United States
Integrated Health Solutions USA, Inc.
Atlanta, Georgia, United States
Integrated Therapeutic Solutions USA, Inc
Hazlehurst, Georgia, United States
Integrated Therapeutic Solutions USA, Inc.
Chicago, Illinois, United States
Integrated Therapeutic Solutions USA, Inc
Prospect, Kentucky, United States
Start Date
December 29, 2021
Primary Completion Date
June 28, 2022
Completion Date
July 8, 2022
Last Updated
July 9, 2024
NCT05085574
NCT05375773
NCT04470583
Lead Sponsor
Leidos Life Sciences
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions